journal article·2025-10-29

Chemically Designed Functional Nanomicelles for Blood–Brain Barrier Crossing

Ankan Kumar Sarkar, Sudipta Jana, Guneet Kaur, Himali Arora, Sourav Barman, Nayana Mukherjee, Santanu Shaw, Amit Ranjan Maity, Pankaj Seth, Nihar R. Jana, Nikhil R. Jana

Nano Letters· Volume 25· Issue 43
Publisher page

Abstract

The blood–brain barrier (BBB) is a specialized semipermeable structure that restricts the exchange of materials between central nervous system parenchyma and blood vessels. Nanocarriers have shown the potential to cross the BBB via receptor-mediated transcytosis (RMT) or adsorption-mediated transcytosis (AMT), though efficiency remains limited. Here, we report two different polymer nanomicelles of 20–60 nm size that efficiently cross the BBB via either RMT or AMT. We have tested their performance in a transwell-based model, tumor spheroid model, and in vivo mice model. We found that lower numbers of receptors per nanomicelle are critical for RMT and direct membrane penetration property of nanomicelle is critical for AMT. Transcytosis can be enhanced by 8–10 times using the optimized nanomicelles that leads to 8 times enhanced penetration in tumor spheroid and 26–35 times enhanced delivery to deep brain tissue. These polymer nanomicelles can be used as nanocarrier for in vivo delivery of therapeutic biomolecules in brain.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Barrier Structure and Function Studies · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Materials Science

Indian Association for the Cultivation of Science

Department of Bioscience and Biotechnology

Indian Institute of Technology

Cellular and Molecular Neuroscience, National Brain Research Centre

Amity Institute of Biotechnology

Amity University

Funding

University Grants Commission · Science and Engineering Research Board

References (29)

Show source-provided references
1. 10.1016/j.nbd.2003.12.01610.1016/j.nbd.2003.12.016 ↗
2. 10.1124/pr.57.2.410.1124/pr.57.2.4 ↗
3. 10.1021/acs.molpharmaceut.4c0044710.1021/acs.molpharmaceut.4c00447 ↗
4. 10.1038/nrn182410.1038/nrn1824 ↗
5. 10.1021/acs.molpharmaceut.4c0060410.1021/acs.molpharmaceut.4c00604 ↗
6. 10.1016/j.pharmthera.2004.08.00110.1016/j.pharmthera.2004.08.001 ↗
7. 10.1016/j.bbcan.2010.04.00110.1016/j.bbcan.2010.04.001 ↗
8. 10.1038/nrclinonc.2011.5810.1038/nrclinonc.2011.58 ↗
9. 10.1016/j.jconrel.2016.05.04410.1016/j.jconrel.2016.05.044 ↗
10. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
11. 10.1021/acsnano.3c1067410.1021/acsnano.3c10674 ↗
12. 10.1016/j.biomaterials.2019.11949110.1016/j.biomaterials.2019.119491 ↗
13. 10.1021/acs.nanolett.1c0299610.1021/acs.nanolett.1c02996 ↗
14. 10.1016/j.mattod.2020.02.00110.1016/j.mattod.2020.02.001 ↗
15. 10.1007/s00259-019-04347-y10.1007/s00259-019-04347-y ↗
16. 10.1021/ar900002610.1021/ar9000026 ↗
17. 10.1039/c0jm00994f10.1039/c0jm00994f ↗
18. 10.1038/s41598-020-75253-910.1038/s41598-020-75253-9 ↗
19. 10.1111/cns.1356910.1111/cns.13569 ↗
20. 10.1038/s41586-024-07314-210.1038/s41586-024-07314-2 ↗
21. 10.1081/DDC-12000148110.1081/DDC-120001481 ↗
22. 10.1007/s11095-007-9379-010.1007/s11095-007-9379-0 ↗
23. 10.1021/acs.accounts.1c0021510.1021/acs.accounts.1c00215 ↗
24. 10.1021/acsami.1c2200910.1021/acsami.1c22009 ↗
25. 10.1021/acsami.3c0924110.1021/acsami.3c09241 ↗
26. 10.1208/s12248-008-9055-210.1208/s12248-008-9055-2 ↗
27. 10.1073/pnas.130715211010.1073/pnas.1307152110 ↗
28. 10.1002/glia.2373410.1002/glia.23734 ↗
29. 10.1016/j.jconrel.2017.12.00510.1016/j.jconrel.2017.12.005 ↗